SCHEMBL7102452

SCHEMBL7102452

COC(=O)c1ccc2[nH]c(=O)n(Cc3cccc(F)c3)c(=O)c2c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CACNA1G O43497 1/20 0.53
HTR3A P46098 1/20 0.53
ALDH1A1 P00352 6/20 0.52
HPGD P15428 6/20 0.52
KMT2A Q03164 5/20 0.52
GAA P10253 4/20 0.52
KDM4E B2RXH2 4/20 0.52
HSD17B10 Q99714 4/20 0.52
GLA P06280 1/20 0.52
PKM P14618 1/20 0.52
HTT P42858 1/20 0.52
NPC1 O15118 1/20 0.50
POLB P06746 1/20 0.50
RAB9A P51151 1/20 0.50
MAPT P10636 5/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
LMNA P02545 1/20 0.48
MAPK10 P53779 1/20 0.48
EPHX2 P34913 2/20 0.47
PPARG P37231 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4258648 0.92 GAA (0.63) CACNA1GHTR3AALDH1A1HPGDKMT2A
SCHEMBL6243745 0.88 MAPT (0.60) ALDH1A1HPGDKMT2AGAAKDM4E
SCHEMBL7197144 0.87 HPGD (0.52) ALDH1A1HPGDKMT2AGAAKDM4E
SCHEMBL7101467 0.85 MAPK1 (0.51) ALDH1A1HPGDKMT2AGAAKDM4E
SCHEMBL7622093 0.83 HPGD (0.54) ALDH1A1HPGDKMT2AGAAKDM4E
SCHEMBL6510914 0.83 KDM4E (0.65) CACNA1GHTR3AALDH1A1KMT2AGAA
SCHEMBL7194154 0.83 HPGD (0.59) ALDH1A1HPGDKMT2AGAAKDM4E
SCHEMBL12822426 0.82 HPGD (0.60) ALDH1A1HPGDKMT2AGAAKDM4E
SCHEMBL27605975 0.81 HPGD (0.52) ALDH1A1HPGDKMT2AGAAKDM4E
SCHEMBL4253579 0.81 GAA (0.65) CACNA1GHTR3AALDH1A1HPGDKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1368324-A1 QUINAZOLINES AS MMP-13 INHIBITORS Warner-Lambert Company LLC (US) 2003-12-10 EP disclosed
US-20020193377-A1 Quinazolines as MMP-13 inhibitors ANDRIANJARA CHARLES (FR) 2002-12-19 US disclosed
WO-2002064572-A1 QUINAZOLINES AS MMP-13 INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2002-08-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020193377-A1 Quinazolines as MMP-13 inhibitors MMP13, MMP9, MMP3 CACNA1G 4075/4885HTR3A 144/4885ALDH1A1 1357/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.